JP2020522535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522535A5 JP2020522535A5 JP2019567345A JP2019567345A JP2020522535A5 JP 2020522535 A5 JP2020522535 A5 JP 2020522535A5 JP 2019567345 A JP2019567345 A JP 2019567345A JP 2019567345 A JP2019567345 A JP 2019567345A JP 2020522535 A5 JP2020522535 A5 JP 2020522535A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- antibody
- seq
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 210000000274 microglia Anatomy 0.000 claims description 7
- 230000006724 microglial activation Effects 0.000 claims description 7
- 206010010254 Concussion Diseases 0.000 claims description 6
- 230000009514 concussion Effects 0.000 claims description 6
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims description 4
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims description 4
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 2
- 101150117962 DUSP1 gene Proteins 0.000 claims description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 2
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 claims description 2
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 claims description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 210000005003 heart tissue Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000002025 microglial effect Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 210000000944 nerve tissue Anatomy 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 230000007505 plaque formation Effects 0.000 claims description 2
- 230000003252 repetitive effect Effects 0.000 claims description 2
- 210000004988 splenocyte Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 16
- 230000004913 activation Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023041296A JP7777096B2 (ja) | 2017-06-06 | 2023-03-15 | ミクログリアの活性化を抑制する方法 |
| JP2024231213A JP2025066722A (ja) | 2017-06-06 | 2024-12-26 | ミクログリアの活性化を抑制する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515711P | 2017-06-06 | 2017-06-06 | |
| US62/515,711 | 2017-06-06 | ||
| PCT/US2018/036261 WO2018226833A1 (en) | 2017-06-06 | 2018-06-06 | Methods of suppressing microglial activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023041296A Division JP7777096B2 (ja) | 2017-06-06 | 2023-03-15 | ミクログリアの活性化を抑制する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522535A JP2020522535A (ja) | 2020-07-30 |
| JP2020522535A5 true JP2020522535A5 (enExample) | 2021-05-27 |
| JP7247113B2 JP7247113B2 (ja) | 2023-03-28 |
Family
ID=64566373
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567345A Active JP7247113B2 (ja) | 2017-06-06 | 2018-06-06 | ミクログリアの活性化を抑制する方法 |
| JP2023041296A Active JP7777096B2 (ja) | 2017-06-06 | 2023-03-15 | ミクログリアの活性化を抑制する方法 |
| JP2024231213A Pending JP2025066722A (ja) | 2017-06-06 | 2024-12-26 | ミクログリアの活性化を抑制する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023041296A Active JP7777096B2 (ja) | 2017-06-06 | 2023-03-15 | ミクログリアの活性化を抑制する方法 |
| JP2024231213A Pending JP2025066722A (ja) | 2017-06-06 | 2024-12-26 | ミクログリアの活性化を抑制する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200165338A1 (enExample) |
| EP (1) | EP3634478A4 (enExample) |
| JP (3) | JP7247113B2 (enExample) |
| CA (1) | CA3066353A1 (enExample) |
| WO (1) | WO2018226833A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021195431A1 (en) * | 2020-03-25 | 2021-09-30 | The Brigham And Women's Hospital, Inc. | Inhaled xenon therapy in neurodegenerative disease |
| WO2021231566A1 (en) * | 2020-05-12 | 2021-11-18 | Massachusetts Institute Of Technology | The use of choline supplementation as therapy for apoe4-related disorders |
| IL297697A (en) * | 2020-06-17 | 2022-12-01 | Tiziana Life Sciences Plc | Preparations and methods for improving chimeric antigen receptor t cell therapies |
| JP2024538064A (ja) * | 2021-10-14 | 2024-10-18 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | ミクログリア活性化を抑制するための方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205280B2 (en) * | 1998-03-11 | 2007-04-17 | Cognosci, Inc. | Methods of suppressing microglial activation |
| ES2526343T3 (es) * | 2004-06-03 | 2015-01-09 | Novimmune Sa | Anticuerpos anti-CD3 y métodos de uso de los mismos |
| US20100209437A1 (en) * | 2005-09-12 | 2010-08-19 | Greg Elson | Anti-CD3 Antibody Fromulations |
| EP3504241B1 (en) * | 2016-08-29 | 2024-05-15 | Tiziana Life Sciences PLC | Anti-cd3 antibody formulations |
-
2018
- 2018-06-06 WO PCT/US2018/036261 patent/WO2018226833A1/en not_active Ceased
- 2018-06-06 EP EP18813852.3A patent/EP3634478A4/en active Pending
- 2018-06-06 JP JP2019567345A patent/JP7247113B2/ja active Active
- 2018-06-06 US US16/619,866 patent/US20200165338A1/en not_active Abandoned
- 2018-06-06 CA CA3066353A patent/CA3066353A1/en active Pending
-
2022
- 2022-03-18 US US17/698,617 patent/US20230039028A1/en active Pending
-
2023
- 2023-03-15 JP JP2023041296A patent/JP7777096B2/ja active Active
-
2024
- 2024-12-26 JP JP2024231213A patent/JP2025066722A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522535A5 (enExample) | ||
| RU2006123481A (ru) | Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний | |
| JP2019523295A5 (enExample) | ||
| JP2020500538A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| JP2013507991A5 (enExample) | ||
| JP2012504634A5 (enExample) | ||
| JP2012504955A5 (enExample) | ||
| JP2020508303A5 (enExample) | ||
| JP2014524748A5 (enExample) | ||
| JP2009511480A5 (enExample) | ||
| JP2011506483A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| JP2018527000A5 (enExample) | ||
| RU2010123888A (ru) | Axl-антитела | |
| JP2006522830A5 (enExample) | ||
| JP2010526087A (ja) | 抗ｉｌ−５抗体を投与するための方法 | |
| CA2494008A1 (en) | Anti-myelin associated glycoprotein (mag) antibodies | |
| JP2019527194A5 (enExample) | ||
| JP2017534646A5 (enExample) | ||
| JP2017507131A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2013521252A5 (enExample) | ||
| JP2019534003A5 (enExample) |